|
2016 Conference Publication The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanomaGoldinger, Simone M., Courtier, Anais, Jaberg-Bentele, Nicoletta F., Schindler, Sabrina, Manuel, Manuarii, Plantier, Nadia, Treillard, Bertrand, Noel, Marlene, Thi Dan Linh Nguyen-Kim, , Raaijmakers, Marieke Ineke Geertje, Kvistborg, Pia, Haanen, John B. A. G., Dummer, Reinhard and Levesque, Mitchell (2016). The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.3026 |
|
2016 Conference Publication A distinct role for eosinophil and neutrophil granulocytes in patients with advanced melanoma receiving selective BRAF inhibitorsCosgarea, I., Franklin, C., Schwamborn, M., Sucker, A., Griewank, K. G., Weide, B., Loquai, C., Hassel, J. C., Kaehler, K. C., Utikal, J., Gutzmer, R., Goldinger, S. M., Paschen, A., Schadendorf, D. and Schilling, B. (2016). A distinct role for eosinophil and neutrophil granulocytes in patients with advanced melanoma receiving selective BRAF inhibitors. 43rd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung-e-V (ADF), Vienna Austria, Mar 10-12, 2016. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patientsHecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patients. 21st Annual Meeting of the German-Society-for-Radiation-Oncology, Hamburg Germany, Jun 25-28, 2015. MUNICH: URBAN & VOGEL. |
|
2015 Conference Publication Association of PD-L1 expression in melanoma with response and prognosis to ipilimumabBrueggemann, Caroline, Weide, Benjamin, Goldinger, Simone M., Konrad, Andreas, Erdmann, Michael, Schadendorf, Dirk, Croner, Roland S., Kraehenbuehl, Lukas, Kaehler, Katharina C., Hafner, Christian, Leisgang, Waltraud, Kiesewetter, Franklin, Dummer, Reinhard, Schuler, Gerold, Stuerzl, Michael and Heinzerling, Lucie (2015). Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2015 Conference Publication A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphomaGoldinger, Simone M., Gobbi, Sharon, Ding, Michelle, Frauchiger, Anna Lisa, Fink-Puches, Regina, Klemke, Claus-Detlev, Dreno, Brigitte, Bagot, Martine, Assaf, Chalid and Dummer, Reinhard (2015). A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2015 Conference Publication Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patientsGoldinger, Simone M., Mangana, Joanna, Frauchiger, Anna L., Kaufmann, Corina, Held, Ulrike, Von Moos, Roger, Romano, Emanuela, Michielin, Olivier, Levesque, Mitchell Paul and Dummer, Reinhard (2015). Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2015 Conference Publication Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trialKunz, Michael, Urosevic-Maiwald, Mirjana, Cozzio, Antonio, Dippel, Michaela, Dreier, Jil, French, Lars E., Goldinger, Simone, Guenova, Emmanuella, Jenni, Daniella, Kamarachev, Jivko, Mangana, Johanna and Dummer, Reinhard (2015). Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trial. NEW YORK: MOSBY-ELSEVIER. |
|
2015 Conference Publication Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigationKraehenbuehl, L., Goldinger, S. M., Matsushita, S., Amann, V. C., Kempf, W., Levesque, M. P. and Dummer, R. (2015). Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigation. HOBOKEN: WILEY-BLACKWELL. |
|
2014 Conference Publication Association of leukocyte counts and adverse events in BRAF inhibitor-treated patientsCosgarea, I., Sondermann, W., Livingstone, E., Griewank, K., Weide, B., Loquai, C., Hassel, J., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Schadendorf, D., Zimmer, L. and Schilling, B. (2014). Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients. HOBOKEN: WILEY-BLACKWELL. |
|
2014 Conference Publication Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitisBjasch, D., Maggio, E. Marquez, Fitsche, A., Moch, H., Goldinger, S. M., Dummer, R. and Mihic-Probst, D. (2014). Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitis. NEW YORK: SPRINGER. |
|
2014 Conference Publication Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanomaSchilling, B., Sondermann, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J. C., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmar, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanoma. 41st Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF), Cologne Germany, Mar 13-15, 2014. HOBOKEN: WILEY. |
|
2013 Conference Publication Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanomaSchilling, B., Suttorp, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kaehler, K., Utikal, J., Gutzmer, R., Al Ghazal, P., Goldinger, S., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2013). Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanoma. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the AutopsyMurer, C., Goldinger, S. M., Maggio, Marques E., Bjasch, D., Stieger, P., Mihic-Probst, D., Schad, K. and Dummer, R. (2013). Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the Autopsy. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication Registry for advanced melanoma in SwitzerlandMangana, J., Frauchiger, A., Goldinger, S. M., Gautschi, M., Von Moos, R., Romano, E., Michielin, O., Levesque, M. P. and Dummer, R. (2013). Registry for advanced melanoma in Switzerland. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsGoldinger, Simone M., Murer, Carla, Stieger, Pascale and Dummer, Reinhard (2013). Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication The genetic landscape of clinical resistance to RAF inhibition in melanomaVan Allen, Eliezer Mendel, Wagle, Nikhil, Carter, Scott L., Sucker, Antje, Farlow, Deborah Norman, Hodis, Fran, Taylor-Weiner, Amara, Berking, Carola, Egberts, Friederike, Hassel, Jessica Cecile, Gogas, Helen, Gutzmer, Ralf, Goldinger, Simone M., Loquai, Carmen, Ugurel, Selma, Zimmer, Lisa, Gabriel, Stacey B., Getz, Gad, Garraway, Levi A. and Schadendorf, Dirk (2013). The genetic landscape of clinical resistance to RAF inhibition in melanoma. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?Mangana, Joanna, Goldinger, Simone M., Schindler, Katja, Rozati, Sima, Frauchiger, Anna L., Rechsteiner, Markus, Moch, Holger, Romano, Emanuela, Kaehler, Katharina C., Michielin, Olivier, Hauschild, Axel, Hoeller, Christoph and Dummer, Reinhard (2013). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkHeinzerling, L., Goldinger, S. M., Voskens, C. J., Loquai, C., Robert, C., Berking, C., Eigentler, T., Fluck, M., Garbe, C., Gutzmer, R., Gleiss, H., Hauschild, A., Hein, R., Justich, A., Keller, U., Klein, C., Mateus, C., Mohr, P., Paetzold, S., Satzger, , Schadendorf, D., Schlaeppi, M., Ulrich, J., Vaubel, J., von Moos, R., Weder, P., Wilhelm, T., Kaehler, K., Goeppner, D. ... Schuler, G. (2013). The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. HOBOKEN: WILEY-BLACKWELL. |
|
2012 Conference Publication OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM)Dummer, R., Goldinger, S., Turtschi, C., Eggmann, N., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R. and Rinderknecht, J. D. (2012). OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM). 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna Austria, Sep 28-Oct 02, 2012. OXFORD: OXFORD UNIV PRESS. |
|
2012 Conference Publication Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts)Goldinger, Simone M., Rinderknecht, Jeannine Desiree, Belloni, Benedetta, Eggmann, Nina and Dummer, Reinhard (2012). Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
